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Aims: The behavioural variant of frontotemporal demen-
tia with a C9orf72 expansion (C9-bvFTD) is characterised
by early changes in social-emotional cognition that are
linked to the loss of von Economo neurons (VENs).
Together with a subset of neighbouring pyramidal neu-
rons, VENs express the GABA receptor subunit theta
(GABRQ). It is not known if the selective vulnerability of
VENs in C9-bvFTD also includes this GABRQ-expressing
population. Methods: We quantified VENs and GABRQ
immunopositive neurons in the anterior cingulate cortex
(ACC) in C9-bvFTD (n = 16), controls (n = 12) and Alz-
heimer’s disease (AD) (n = 7). Second, we assessed VENs
and GABRQ-expressing populations in relation to the
clinicopathological profiles. Results: We found the num-
ber of VENs and GABRQ-expressing neurons and their
ratio over the total layer 5 neuronal population was lower
in C9-bvFTD compared to control and AD. C9-bvFTD
donors with underlying TDP43 type A pathology in the
ACC showed the highest loss of GABRQ-expressing neu-
rons. C9-bvFTD donors that did not present with motor
neuron disease (MND) symptoms in the first half of their
disease course showed a prominent loss of GABRQ-ex-
pressing neurons compared to controls. C9-bvFTD donors
with no symptoms of psychosis showed a higher loss com-
pared to controls. Across all donors, the number of VENs
correlated strongly with the number of GABRQ-expressing
neurons. Conclusion: We show that VENs, together with
GABRQ-expressing neurons, are selectively vulnerable in
C9-bvFTD but are both spared in AD. This suggests they
are related and that this GABRQ-expressing population
of VENs and pyramidal neurons, is a key modulator of
social-emotional functioning.
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Introduction
The behavioural variant of frontotemporal dementia
(bvFTD) is the main clinical manifestation of
frontotemporal lobar degeneration (FTLD) [1]. In up to
20% of cases the disease is familial, with a repeat
expansion in the C9orf72 gene being the most frequent
genetic cause of bvFTD (C9-bvFTD) [2]. Patients with
the expansion can present with a spectrum of symp-
toms, including motor neuron disease (MND)/amy-
otrophic lateral sclerosis (ALS) [2]. Psychotic
symptoms, such as delusions and hallucinations, are
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also commonly seen in C9-bvFTD patients, during or
prior to the onset of dementia [3]. Pathologically, in
patients with C9-bvFTD the aggregation of phosphory-
lated transactive response DNA binding protein 43 kDa
(TDP43) is most likely linked to neurodegeneration [4].
This TDP43 pathology has been subdivided into distinct
subclasses, types A-E, based on its cortical laminar dis-
tribution and morphology [5]. In C9-bvFTD, the com-
monly observed subtypes are TDP43 type A and B
[6,7]. The clinical relevance of the different laminar dis-
tribution patterns within the C9-bvFTD donors is cur-
rently unclear.
Clinically, progressive social-emotional processing
deficits are one of the earliest symptoms seen in bvFTD,
and have been linked to a specific neuronal type, the
von Economo neurons (VENs) [8,9]. VENs are selec-
tively vulnerable in the earliest stages of the disease
and have been implicated in the behavioural symptoms
of bvFTD [8–12]. VENs have a unique morphology and
are found mainly in layer 5 of the human anterior cin-
gulate cortex (ACC) and frontoinsular cortex (FI) [13].
They are distinguished from pyramidal neurons by
their large bipolar cell body and thick dendrites [14].
VENs have been identified with a similar regional distri-
bution in highly social mammals, such as primates,
cetaceans and elephants, but are not found in common
laboratory animals, such as mice and rats [15–17].
Together with a subset of neighbouring layer 5b pyra-
midal neurons in the ACC and FI, VENs possess a
monoaminergic phenotype and express the GABA
receptor subunit theta (GABRQ) and are therefore part
of a unique cortical neuronal population [18]. Cur-
rently, it is not known if the selective vulnerability of
VENs in bvFTD includes the neighbouring GABRQ-ex-
pressing pyramidal neurons.
Here, we aim to investigate if VENs are part of a lar-
ger neuronal population by quantifying the selective
vulnerability of VENs and related GABRQ-expressing
neurons in C9-bvFTD in the ACC. In addition, we aim
to study the clinicopathological relationships with a
focus on the GABRQ-expressing population and VENs.
Materials and methods
Subjects
Post-mortem brain tissue was obtained from the
Netherlands Brain Bank and the department of
pathology, Amsterdam University Medical Centre, loca-
tion VUmc, Amsterdam, The Netherlands. Donors were
seen at either VUmc or Erasmus Medical Centre, Rot-
terdam, The Netherlands. We included patients with
bvFTD as a result of C9orf72 mutation (genetically con-
firmed at Erasmus Medical Centre, Rotterdam, n = 16),
donors with typical amnestic presentation of Alzhei-
mer’s disease (AD) (n = 7), and age-matched neurologi-
cally unaffected controls (n = 12) (Table 1 and
Table S1). Donors with concomitant pathology were
excluded from the study. Extensive clinical reports were
available from all donors.
Sample selection
Within the ACC, VENs have a greater decrease in a
rostrocaudal gradient [19]. Therefore, we sampled the
ACC in a consistent manner where we took the ACC
adjacent to the genu to minimize variation. After
4 weeks of fixation in formalin, the material was
embedded in paraffin and cut into a series of sequential
10 lm sections.
Immunohistochemical procedures
On the sequential slides, immunohistochemical proce-
dures were performed with antibodies against GABA
receptor subunit epsilon (GABRE: HPA045918, Sigma
Aldrich, St. Louis, MO) that was used for outlining
layer 5a, GABRQ (HPA002063; Sigma Aldrich) and
pTDP43 (CAC-TIP-PTD-M01, Cosmo Bio, Japan).
Briefly, slides were deparaffinised and then incubated in
0.3% H2O2 in phosphate buffer saline (PBS; pH 7.4) for
30 min to block endogenous peroxidase activity. Sec-
tions were then washed with PBS (3 9 5 min) and
heat-induced antigen retrieval was performed in citrate
buffer (pH 6.0) using the autoclave (121°C for 5 min).
After washing, sections were incubated in 10% normal
goat serum in PBS (1:50) for 30 min followed by incu-
bation in primary antibody (GABRQ 1:750; GABRE
Table 1. Demographic and clinical data of donors
n M/F Age Disease duration
C9-bvFTD 16 6/10 66.5 (40–77) 7 (2–11)
AD 7 4/3 82 (69–96) 8 (3–12)
Control 12 6/6 64 (51–86) n/a
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1:1000, pTDP43 1:8000) for 1 h (pTDP43 and
GABRE) or overnight at 4°C (GABRQ). After washing,
sections were incubated with HRP-labelled Envision
(K5007; DAKO, Glostrup, Denmark), washed and then
visualization of immunostaining was seen with chro-
mogen 3,30-diaminobenzidine (DAB; K5007; DAKO).
Finally, sections were counterstained with haema-
toxylin, dehydrated, and cover slipped with Quick-D
(Klinipath, Duiven, The Netherlands). Negative controls
for each primary antibody were included by omitting
the primary antibody and showed no immunoreactiv-
ity, brainstem sections were used for positive controls
for GABRE and GABRQ [18].
Quantification of GABRQ-expressing cortical
neurons
To quantify GABRQ expression, we analysed the GABRQ
stained slides from the ACC using Stereoinvestigator soft-
ware (V11.6.2). First, the cortex was outlined using the
grey-white matter border. Second, layer 5 was delineated
using one slide stained with GABRE and the sequential
section with GABRQ, where GABRE depicted the apical
layer 5 border and GABRQ the lower layer 5b border
(Figure S1). Within layer 5, all neurons were counted
using the Meander scan option in Stereoinvestigator and
divided into 4 categories: (1) GABRQ-expressing VENs,
(2) GABRQ-expressing pyramidal neurons, (3) GABRQ-
negative VENs and (4) GABRQ-negative pyramidal neu-
rons (Figure 1). VENs were identified based on their typi-
cal morphological profile [19]: a long elongated soma
with one apical and one basal dendrite. In contrast,
pyramidal neurons were identified based on their more
rounded or tear drop soma with two basal dendrites and
were counted if their cell body was larger than 10 lm.
Quantification of TDP43 pathology
A sequential slide was used to identify the molecular
subclass of TDP43 pathology and quantify the burden
of phosphorylated TDP43 (pTDP43) pathology in layer
5. Briefly, donors were classed as type A when inclu-
sions and short threads were observed to be predomi-
nantly in the superficial layers. If mainly cytoplasmic
inclusions were seen with no preference for layers, type
B was denoted. If long threads were seen predomi-
nantly in the superficial layers type C was charac-
terised. Type D was given if frequent lentiform
intranuclear inclusions were seen. Finally, if the ACC
showed a strong granular intracellular and extracellu-
lar spread with no intracellular inclusions, type E was
considered [5]. The burden of pathology in layer 5 was
quantified using the Meander scan option in Stereoin-
vestigator. The outline of the delineation was adjusted
to the slightly different plane of tissue. The types of
pathology were scored separately: threads larger than
10 lm, extracellular aggregates, intraneuronal large
round aggregates and intraneuronal punctate granular
aggregates [5]. The burden was defined as the com-
bined scores of all types of pTDP43 pathology.
Clinical features
The medical history was used to determine the medical
profile of the donors. For controls, no neurological symp-
toms were recorded. For C9-bvFTD, the following symp-
toms were noted as present if donors presented with
them in the first half of their disease course: memory
symptoms, speech symptoms, and signs of MND [20,21].
Symptoms of psychosis, such as delusions and hallucina-
tions, were considered present if they were reported at
any given time during the disease progression. The pres-
ence of the symptoms was used to subdivide the C9-
bvFTD donors based on their clinical profile.
Statistics
Statistics were performed using SPSS 22. Pearson cor-
relation was used to assess correlation and differences
between groups were assessed using one-way ANOVA
with Tukey’s post-hoc analysis.
Results
Numbers of VENs and GABRQ-expressing neurons
are correlated and selectively vulnerable in C9-
bvFTD
In this study we quantified the number of VENs and
GABRQ-expressing neurons (VENs and pyramidal neu-
rons) in the ACC of 16 C9-bvFTD, 12 control and 7
AD donors. We found that on average there was a
57% reduction in number of VENs in C9-bvFTD when
compared to control (P = 0.01) (Figure 2d). Using an
ANOVA, a significant difference was seen in the num-
ber of VENs present between the three groups; controls,
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AD and C9-bvFTD (F(2) = 4.92, P = 0.01). A similar
finding was also seen in the number of GABRQ-express-
ing neurons, with a 51% reduction seen in C9-bvFTD
compared to control, which was statistically significant
(P < 0.001) (Figure 2e). No significant difference in
GABRQ-expressing neurons between AD and controls
was detected. This indicates that the GABRQ-expressing
population is spared from neurodegeneration in AD
and selectively vulnerable in C9-bvFTD. No significant
difference in total neuronal population of layer 5 was
found (F(2) = 2.20, P = 0.13).
To determine if VENs are part of a larger GABRQ-ex-
pressing population we correlated the total number of
VENs with the total number of GABRQ-expressing neu-
rons and found there was a significant correlation seen
across all donors included in this study (P = 0.65,
P < 0.001).
The ratio of GABRQ-expressing neurons was calcu-
lated by dividing the total number of GABRQ-express-
ing neurons over the total layer 5 neuronal population.
Using an ANOVA, a significant difference was found in
ratio between the three groups (F(2) = 7.72,
P = 0.02). Tukey post-hoc analysis revealed a signifi-
cant decline of ratio in donors with C9-bvFTD com-
pared to controls (P = 0.02) and compared to AD
donors (P = 0.004) (Figure 2f).
(a)
(b) (c) (d) (e)
Figure 1. GABRQ expression in the ACC. GABRQ expression in layer 5b of the ACC (a). GABRQ is expressed in VENs (b) and a subset of
neighbouring pyramidal neurons (c) but is not seen in all layer 5b pyramidal neurons (e). Though infrequent, GABRQ-negative VENs are
also present (d) (14). Scale bars represent 100 lm (a) and 25 lm (b–e).
© 2019 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
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Relation between VENs and GABRQ-expressing
neurons and TDP43 pathology
Since TDP43 is believed to play an integral role in neu-
rodegeneration, we next looked at the TDP43 pathol-
ogy in the ACC [5]. Of the 16 donors with C9-bvFTD
TDP43 pathology, seven were subdivided into molecu-
lar subclass TDP43 type A, six TDP43 type B, and
three TDP43 type E. When we split the groups accord-
ing to their molecular subclass we found there was a
reduction in number of VENs across all subclasses with
type A showing the greatest loss (P = 0.046) (Fig-
ure 3d). A comparable pattern was also seen in the
number of GABRQ-expressing neurons, with all reach-
ing significance (type A: P < 0.001; type B: P = 0.002;
type E: P = 0.04) (Figure 3e). In contrast, TDP43 type
A donors revealed the largest drop in the ratio of
GABRQ-expressing neurons compared to controls
whereas TDP43 type B and type E showed a less promi-
nent loss (P = 0.01) (Figure 3f). Using the layer 5
outline from the GABRQ-quantification, pTDP43
pathology was quantified on a sequential slide. The dif-
ferent types and burden of pathology did not correlate
with the ratio and neuronal loss. pTDP43 inclusions in
VENs were only seen in 1 of the 16 cases analysed,
indicating that in our cohort not the burden, but the
distribution as defined by molecular subclasses is
related to the GABRQ-expressing neuronal loss.
Relation between VENs and GABRQ-expressing
neurons and clinical features
In our C9-bvFTD cohort, disease duration varied from
2 to 11 years (median 7). We investigated the presence
of non-behavioural symptoms in the first half of the
donors’ disease course. A lower ratio of GABRQ-ex-
pressing neurons was observed in C9-bvFTD donors
without MND symptoms present in the first half of their
disease course compared to controls (P = 0.03). This
difference was not seen in C9-bvFTD donors with these
Figure 2. VENs and GABRQ-expressing neurons are reduced in C9-bvFTD. The GABRQ-expressing population is reduced in C9-bvFTD
compared to controls and AD, the black arrowheads indicate GABRQ-positive VENs and the white arrows GABRQ-positive pyramidal
neurons (a–c). Quantification of the number of VENs showed a significant reduction in C9-bvFTD compared to control (d). Similarly, in
C9-bvFTD there was a significant reduction in number of GABRQ-expressing neurons (VENs and pyramidal) compared to control and AD
(e). The ratio of GABRQ-expressing neurons over the total number of neurons in layer 5 showed GABRQ-expressing neurons were
selectively targeted in C9-bvFTD, with a significant reduction seen when compared to controls and AD (f). Scale bar represent 50 lm.
Error bars represent standard error of the mean (SEM). *P < 0.05, **P < 0.01.
© 2019 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
on behalf of British Neuropathological Society.
Von Economo neurons are part of a larger neuronal population 5
symptoms present in the first half of their disease
course (P = 0.05). In contrast, C9-bvFTD donors pre-
senting with memory and speech symptoms in the first
half of their disease course had a lower ratio of
GABRQ-expressing neurons compared to control
(P = 0.01 and P = 0.02) (Figure 4a–c). Four donors
with C9-bvFTD reported psychotic symptoms through-
out their disease duration. The ratio of GABRQ-express-
ing neurons was significantly lower in donors with no
psychosis present throughout their disease duration
compared to controls (P < 0.01), which was not
observed in donors with presence of psychotic symp-
toms (P = 0.80; Figure 4d) [10].
Discussion
Here, we have shown that the selective vulnerability of
VENs in C9-bvFTD extends to the larger population of
cortical GABRQ-expressing neurons in the ACC. The
selective vulnerability of VENs in bvFTD and other dis-
eases with altered social cognition has been widely dis-
cussed in literature [8–12,22–,24] but this is the first
work to show that VENs are part of a larger population
of neurons linked to social cognition.
VENs and GABRQ-expressing neurons are part of a
similar neuronal population
We quantified the number of VENs and GABRQ-ex-
pressing neurons (VENs and pyramidal neurons) in all
donors and found that the selective vulnerability of
VENs in C9-bvFTD is shared with GABRQ-expressing
neurons and that this GABRQ-expressing neuronal pop-
ulation is spared in AD, similar to what has been
reported for VENs [8–11]. Moreover, a significant corre-
lation is seen between VEN number and GABRQ-
Figure 3. TDP43 type A pathology is related to a higher loss of VENs and GABRQ-expressing neurons. In the ACC, TDP43 subtypes
were characterised and classified accordingly, where TDP43 type A (a) was given when cytoplasmic inclusions and threads (a inset) were
observed predominantly in layer 2. TDP43 type B distribution (b) was given if mainly cytoplasmic inclusions (b inset) with no preference
for a layer was seen. TDP43 type E (c) was considered if a strong granular intracellular and extracellular staining (c inset) was seen with
no intracellular inclusions. A similar reduction in number of VENs was seen across all TDP43 types, with type A reaching significance
(d). The number of GABRQ-expressing neurons followed the same trend as VENs, with all reaching significance (e). Donors with TDP43
type A pathology had the greatest decline in ratio when compared to control (f). Though a reduction is also seen in cases with TDP43
type B and type E this was less prominent and did not reach significance. Scale bars represent 50 lm (a–c) and 25 lm (insets). Error
bars represent SEM. *P < 0.05, **P < 0.01.
© 2019 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
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expressing neurons across healthy donors and donors
with AD and C9-bvFTD. This indicates that the loss
and sparing of these neuronal types in dementia occurs
concurrently, and supports the hypothesis that VENs
and GABRQ-expressing neurons are related and
together form a larger cortical population [18]. Addi-
tionally, the sparse expression of GABRQ in pyramidal
neurons in layer 5 in the frontal and temporal cortex is
in line with the recent uncovering of sparse VENs seen
in the frontal cortex [18,25,26]. It is possible that the
GABRQ-expressing neuronal population also includes a
small number of neurons outside the ACC and FI.
Due to their selective vulnerability, regional distribu-
tion and phylogenetic distribution among different spe-
cies, VENs have been linked to higher social cognition
[8–10,15,17,19,27–,29]. In other diseases where social
cognition is altered such as autism and schizophrenia,
the numbers of VENs are also altered compared to con-
trol donors [22–24,30]. Our findings suggest that the
neuronal population involved in these complex social
processes is larger than initially assumed. This provides
opportunities to expand the study of VENs and GABRQ-
expressing neurons in greater detail across diseases
where social cognition is altered.
The biochemical similarities of VENs and GABRQ-ex-
pressing neurons also include the expression of vesicu-
lar monoamine transporter 2 (VMAT2) [18]. The
monoaminergic properties and a specialized GABA
receptor subtype reveal that these neurons could relay
information in a unique manner distinct to their neigh-
bouring neurons. This study utilized immunohisto-
chemistry to visualize GABRQ expression and is
therefore limited as low levels of protein expression
cannot be visualized. A small number of VENs do not
show detectable expression levels of GABRQ using
immunohistochemistry, however, it is unclear if these
neurons do not express GABRQ at all. Although unli-
kely, one possibility could be that the neighbouring
GABRQ-negative neurons in the C9-bvFTD donors have
simply lost their expression or do not reach detectable
levels of GABRQ as a result of disease pathogenesis,
and therefore cannot be distinguished from other layer
5b pyramidal neurons that never expressed the sub-
unit. Loss of receptor expression would result in an
uncoupling of signalling pathways and functionality of
the neurons. We therefore hypothesize that the effect of
neurodegeneration or loss of GABRQ expression would
have similar effects on the signal processing.
Figure 4. Decreased ratio of GABRQ-expressing neurons is associated with clinical features. C9-bvFTD donors presenting with memory
symptoms (a) and speech symptoms (b) but not MND symptoms (c) in the first half of their disease course had a significantly lower ratio
of GABRQ-expressing neurons compared to controls. Donors without psychotic symptoms had a reduction in the ratio of GABRQ-
expressing neurons compared to controls, which was not seen in donors with psychotic symptoms (d). Error bars indicate SEM.
*P < 0.05, **P < 0.01.
© 2019 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
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GABRQ-expressing neurons are selectively
vulnerable in donors with C9-bvFTD with different
pathological subclasses
In our analysis, we have shown that donors with
underlying TDP43 type A pathology in the ACC have a
higher loss of GABRQ-expressing neurons in layer 5
compared to TDP43 types B and E, with TDP43 type E
donors having the least GABRQ-expressing neuronal
loss. This indicates that within the clinical spectrum,
there is also a pathological spectrum where patients
with distinct local TDP43 aggregation distribution pat-
terns also display different patterns of neuronal loss. It
has been suggested that the TDP43 type E pathology
represents a MND-related state of TDP43 pathology
[31,32], however in our cohort, none of the donors
with granular pathology in the ACC displayed promi-
nent MND symptoms. No contribution of layer 5
pTDP43 burden on neuronal loss was found in the
ACC and remarkably, only one case showed neuronal
inclusions in VENs. A recent study reported that
though TDP43 inclusions were much lower in C9-
bvFTD/MND compared to sporadic bvFTD, VENs were
fourfold more prone to TDP43 inclusions compared to
their neighbouring layer 5 neurons in C9-bvFTD/MND
in the FI [33]. In these C9-bvFTD/MND donors they
also reported that VENs lacking nuclear TDP43 and
TDP43 inclusions, termed TDP43-depleted neurons,
were just as frequent as those with inclusions, however
this varied between donors [33]. Based on these find-
ings, it is possible that our C9-bvFTD donors possess
TDP43-depleted neurons, which could explain why we
did not observe inclusions in VENs. It is also important
to note there may be regional differences in TDP43
pathology, with the FI VENs showing more TDP43
pathology compared to the VENs in the ACC.
Clinical features
Our cohort shows no difference in the GABRQ-express-
ing ratio within the C9-bvFTD donors based on pres-
ence of memory, speech and MND symptoms in the
first half of their disease course. Previously, a signifi-
cant difference in number of VENs was found between
donors with predominantly MND symptoms and bvFTD
[10]. Our cohort had three donors that reported MND
symptoms in the first half of their disease duration,
however, in all donors this was accompanied by beha-
vioural symptoms; in this study no C9orf72 donors
were available with pure MND. Nonetheless, a lower
ratio of GABRQ-expressing neurons was observed in
relation to the absence of MND symptoms compared to
controls, indicating that the pure behavioural variant
of C9-bvFTD without MND is associated with a lower
ratio of GABRQ-expressing neurons. Concerning psy-
chotic symptoms, we found similar results to Yang
et al. 2017, where C9orf72 donors with psychotic
symptoms had a higher density of VENs compared to
donors without psychotic symptoms [10]. This observa-
tion also extends to the GABRQ-expressing population,
indicating that the GABRQ-expressing population and
VENs are not key-regulators of psychotic symptoms in
C9-bvFTD.
GABRQ can be specifically modulated
The findings of this study have impact on the therapeu-
tic intervention of bvFTD. GABRQ is expressed in other
regions of the brain, including hypothalamus, amygdala
and brainstem structures such as periaqueductal grey
and locus coeruleus [18,34–37]. Possible subunit assem-
bly partners of GABRQ have been studied in rat locus
coeruleus where GABRQ is reported to be co-expressed
with GABRE [34]. In the ACC and FI of the human cor-
tex, a clear segregation of the GABA receptor subunits
can be observed, with GABRE in layer 5a and GABRQ
in layer 5b, indicating that the subunits are not co-ex-
pressed in the human cortical population. This provides
an opportunity for specific target modulation based on
the unique GABA receptor subunit expression.
To conclude, we have shown that VENs are part of a
larger neuronal population characterized by GABRQ
expression. This population is selectively vulnerable in
C9-bvFTD and spared in typical amnestic AD neurode-
generation. This suggest that this neuronal population
is a key modulator of social and emotional functioning.
The selective vulnerability is found to be more promi-
nent in donors with TDP43 type A laminar pathology,
compared to type B and E, indicating that the distribu-
tion of TDP43 in the cortex determines the GABRQ-ex-
pressing neuronal loss. These findings widen the
possibilities of specific modulation of this neuronal pop-
ulation, as GABRQ appears to be expressed in a unique
receptor subunit assembly combination.
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